Repression of DOK7 mediated by DNMT3A promotes the proliferation and invasion of KYSE410 and TE-12 ESCC cells.
Increasing evidence shows that aberrant epigenetic regulation of tumor suppressor genes is a contributing factor to their altered expression in esophageal squamous cell carcinoma (ESCC). In the current study, we investigate the role of DOK7 in ESCC cells. We found that enforced expression of DOK7 inhibited the proliferation and invasion of ESCC cells. We also found that treatment of ESCC cells with the DNA methylation inhibitor, 5-aza-2-deoxycytidine (5-azadC), induced the demethylation of DOK7 in promoter and DOK7 expression. Moreover, silencing DNMT3A decreased methylation of DOK7 and increased DOK7 expression, followed by repressing the proliferation and invasion of ESCC cells. Collectively, our data indicated that silencing DNMT3A inhibits proliferation and invasion in ESCC cells by inducing demethylation of DOK7.
Department of Medical Oncology, Anhui Provincial Cancer Hospital, Anhui Provincial Hospital,107 Huanhu Road East, Hefei, 230031, People's Republic of China.
Shou-Mei
SM
Yang
Department of Medical Oncology, Anhui Provincial Cancer Hospital, Anhui Provincial Hospital,107 Huanhu Road East, Hefei, 230031, People's Republic of China. Electronic address: yangsm290@sohu.com.
Su-Yi
SY
Li
Department of Medical Oncology, Anhui Provincial Cancer Hospital, Anhui Provincial Hospital,107 Huanhu Road East, Hefei, 230031, People's Republic of China.
Hao-Bin
HB
Yu
Department of Medical Oncology, Anhui Provincial Cancer Hospital, Anhui Provincial Hospital,107 Huanhu Road East, Hefei, 230031, People's Republic of China.
Jie-Ru
JR
Li
Department of Medical Oncology, Anhui Provincial Cancer Hospital, Anhui Provincial Hospital,107 Huanhu Road East, Hefei, 230031, People's Republic of China.
Lei-Lei
LL
Sun
D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects / Q000235:genetics*; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000235:genetics*; D019175:DNA Methylation / Q000187:drug effects / Q000235:genetics; D000090205:DNA Methyltransferase 3A; D000077209:Decitabine; D044127:Epigenesis, Genetic / Q000187:drug effects / Q000235:genetics; D004938:Esophageal Neoplasms / Q000235:genetics; D000077277:Esophageal Squamous Cell Carcinoma; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics*; D020868:Gene Silencing / Q000187:drug effects / Q000502:physiology; D006801:Humans; D009124:Muscle Proteins / Q000235:genetics*; D009361:Neoplasm Invasiveness / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000187:drug effects / Q000235:genetics
C000717967:DNMT3A protein, human; C511692:DOK7 protein, human; D009124:Muscle Proteins; D000077209:Decitabine; D004248:DNA (Cytosine-5-)-Methyltransferases; D000090205:DNA Methyltransferase 3A; D001374:Azacitidine
DNMT3A; DOK7; Esophageal squamous cell carcinoma